BioTech IP Review

Inorganic Salts of Nicotinamide Mononucleotide as Anti‑Aging Agents

  • Application Number: 18/744,312 (U.S. application; filed in 2024)
  • Filing Date: June 14, 2024
  • First Publication Date: May 8, 2025
  • Owner/Assignee: Life Biosciences Inc.
  • Status: Pending patent application (not yet issued as a granted patent)

What This Patent Covers

This patent application claims inorganic salt forms of nicotinamide mononucleotide (NMN) and related compositions and methods for their use in treating or preventing age‑related disorders:

1. Composition Claims

  • The invention includes specific inorganic salt forms of nicotinamide mononucleotide that improve features such as stability and solubility relative to neutral NMN, which is often unstable and degrades quickly in solution.

2. Therapeutic Uses

  • Methods of treating or preventing age‑associated diseases and conditions, particularly disorders linked to NAD⁺ decline (such as infertility tied to age, metabolic dysfunction, etc.), are claimed.

3. Methods of Administration

  • The application describes administering these NMN salts therapeutically to subjects to ameliorate aging mechanisms, including cellular NAD⁺ restoration and related biological pathways involved in the aging process.

4. Applications in Assisted Reproductive Technologies

  • The salt compositions are also described for use in improving oocyte or blastocyst quality and maturation ex vivo, such as in in vitro fertilization (IVF) media that enhance NAD⁺ production prior to implantation.

Why This Patent Is Important

  • Strategic IP in Aging Biology: Nicotinamide mononucleotide (NMN) and its derivatives are central to efforts to boost cellular NAD⁺, a key metabolite whose levels diminish with age and are linked to multiple age‑related disease processes.
  • Improved Drug Properties: The claimed inorganic salt forms can offer enhanced stability and bioavailability over neutral NMN, making them more suitable as a therapeutic product rather than a dietary supplement, which carries regulatory and market implications.
  • Broad Potential Utility: By covering both composition and use in age‑related disorders, this patent could support a range of future therapeutic products targeting aging mechanisms — not just one specific disease.
  • Relevance to Life Biosciences Strategy: Although Life Biosciences is better known for its partial epigenetic reprogramming platform, this patent shows the company is also building foundation IP in metabolic rejuvenation chemistry aimed at aging biology.

Summary

The U.S. Patent Application No. 18/744,312 covers inorganic salts of nicotinamide mononucleotide and their medicinal uses to treat age‑related disorders — particularly by enhancing NAD⁺ levels and aiding cellular processes compromised by aging. This application is strategically important because it broadens Life Biosciences’ aging‑related intellectual property and could underpin future anti‑aging therapeutics with improved stability and biological activity compared to earlier NMN forms.

Leave a comment